Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - simvastatin -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - simvastatin -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - simvastatin, quantity: 5 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; pregelatinised maize starch; butylated hydroxyanisole; lactose monohydrate; citric acid monohydrate; ascorbic acid; titanium dioxide; hypromellose; hyprolose; purified talc; iron oxide yellow - adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with simvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. simvastatin is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - famciclovir -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - famciclovir -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - famciclovir -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - metoprolol tartrate -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - metoprolol tartrate -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 5 mg - tablet, uncoated - excipient ingredients: iron oxide red; lactose monohydrate; sodium bicarbonate; sodium stearylfumarate; pregelatinised maize starch; croscarmellose sodium - ? treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. ,? post mi heart failure ,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularization procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.